Kymera Therapeutics, Inc. Common Stock
KYMRKymera Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degradation therapies to treat serious diseases. Using its proprietary Pegasus platform, the company designs small molecules to selectively degrade disease-causing proteins, aiming to address previously "undruggable" targets in areas such as inflammation, oncology, and genetic disorders. Founded to leverage novel approaches in drug discovery, Kymera aims to transform medicine through innovative targeted degradation strategies.
Company News
Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6 million on July 7, 2026, following a 170% stock surge over 12 months. The sale involved exercising options at $2.08 and selling at $119 per share under a pre-scheduled Rule 10b5-1 trading plan. Despite the sale, Mainolfi retains 666,568 shares worth $79.5 million and 90,000 options,...
Kymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at D...
Kymera Therapeutics announced preclinical data for KT-579, an oral IRF5 degrader, demonstrating disease-modifying activity in lupus models comparable or superior to approved therapies. The compound showed consistent activity across multiple disease pathways including Type I interferons and pro-inflammatory cytokines. Phase 1 healthy volunteer tri...
Kymera Therapeutics announced presentations of Phase 1b clinical data for KT-621, its first-in-class oral STAT6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses. The data demonstrated deep STAT6 degradation in blood and skin, reductions in Type 2 inflammatory biomarkers, and favorable safety profile....
Kymera Therapeutics announced participation in upcoming investor conferences in May 2026 and presented preclinical data for KT-579, its first-in-class oral IRF5 degrader for inflammatory bowel disease, showing activity comparable or superior to approved therapies. The company has Phase 1 data expected in H2 2026 and ongoing Phase 2b trials for KT...
